Darunavir
The Chinese authorities have indicated that Darunavir against 2019-nCoV
may be successful. In vitro cell studies have shown that
Darunavir can effectively inhibit replication of the new strain, at a
concentration of 300 micromolar, according to preliminary research
Darunavir, in conjunction with cobicistat, will be used in patients with
COVID-19 pneumonia in trial number NCT04252274 [50]. Such a mixture
is currently approved by the United States Food and Drug Administration
(FDA) in AIDS treatment. Darunavir is another HIV protease inhibitor and
cobicistat, like ritonavir, is a booster to enhance the pharmacokinetics
and pharmacodynamics of darunavir by inhibiting cytochrome P450 (CYP3A)
[53] [54]. Due to in vitro evidence that supports its ability to
fight this infection, Darunavir is being studied as a potential cure for
SARS-CoV-2, the coronavirus responsible for COVID-19[52]. Clinical
trials are under progress and are scheduled to end in August
2020.Although, HIV-1 protease inhibitor is currently being evaluated in
a clinical trial (NCT04252274), but no in vitro or human data
exist to support its use against 2019-nCoV.